Aytu BioPharma Inc (STU:AY20)
€ 2.88 0.04 (1.41%) Market Cap: 16.19 Mil Enterprise Value: 13.39 Mil PE Ratio: 0 PB Ratio: 0.58 GF Score: 32/100

Q1 2024 Aytu Biopharma Inc Earnings Call Transcript

Nov 14, 2023 / 09:30PM GMT
Release Date Price: €2.56 (-3.03%)
Roger Weiss
Lytham Partners - IR

Good afternoon, everyone, and thank you for joining us for Aytu BioPharma's fiscal 2024 first-quarter financial results conference call for the period ended September 30, 2023. Joining us on today's call is Aytu's CEO, Josh Disbrow, and the company's Chief Financial Officer, Mark Oki. At the conclusion of today's prepared remarks, we'll open the call for a question-and-answer session. I'd like to remind everyone that today's call is being recorded. A replay of today's call will be available by using the telephone numbers and conference ID provided in the earnings press release issued earlier today.

Finally, I'd also like to call your attention to the customary Safe Harbor disclosure regarding forward-looking information. The conference call today will contain certain forward-looking statements, including statements regarding the goals, strategies, beliefs, expectations, and future potential operating results of Aytu BioPharma. Although management believes these statements are reasonable based on estimates, assumptions, and projections as of today, these

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot